Dysregulation of Insulin Signaling, Glucose Transporters, O-GlcNAcylation, and Phosphorylation of Tau and Neurofilaments in the Brain

Implication for Alzheimer’s Disease

Yanqiu Deng,*† Bin Li,* Ying Liu,* Khalid Iqbal,* Inge Grundke-Iqbal,* and Cheng-Xin Gong*

From the Department of Neurochemistry,* New York State Institute for Basic Research in Developmental Disabilities, Staten Island, New York; and the Department of Pathophysiology,† Tianjin Medical University, Tianjin, China

Recent studies have suggested a possible role of insulin dysfunction in the pathogenesis of sporadic Alzheimer’s disease (AD). In AD, brain glucose metabolism is impaired, and this impairment appears to precede the pathology and clinical symptoms of the disease. However, the exact contribution of impaired insulin signaling to AD is not known. In this study, by using a nontransgenic rat model of sporadic AD generated by intracerebroventricular administration of streptozotocin, we investigated insulin signaling, glucose transporters, protein O-GlcNAcylation, and phosphorylation of tau and neurofilaments in the brain. We found impaired insulin signaling, overactivation of glycogen synthase kinase-3β, decreased levels of major brain glucose transporters, downregulated protein O-GlcNAcylation, increased phosphorylation of tau and neurofilaments, and decreased microtubule-binding activity of tau in the brains of streptozotocin-treated rats. These results suggest that impaired brain insulin signaling may lead to overactivation of glycogen synthase kinase-3β and down-regulation of O-GlcNAcylation, which, in turn, facilitate abnormal hyperphosphorylation of tau and neurofilaments and, consequently, neurofibrillary degeneration. (Am J Pathol 2009, 175:2089–2098; DOI: 10.2353/ajpath.2009.090157)

Alzheimer’s disease (AD), the most devastating chronic neurodegenerative disease in adults, causes dementia in, and eventually, death of the affected individuals. In less than 1% of cases, AD is caused by autosomal dominant mutations of presenilin-1, presenilin-2, or β-amyloid precursor protein. Most AD cases are sporadic and are believed to result from multiple etiologic factors including genetic susceptibility (such as the ApoE4 allele) and environmental and metabolic factors.1 One of these factors, impaired brain glucose metabolism, can be detected many years before the appearance of clinical symptoms of AD.2 We recently found that altered O-GlcNAcylation, an O-linked post-translational modification of nucleoeytoplasmic proteins by a monosaccharide β-N-acetylglucosamine (O-GlcNAc), of the microtubule-associated protein tau, links the impairment of brain glucose metabolism to hyperphosphorylation of tau.3,4 On the basis of these findings, we hypothesized that the impairment of brain glucose metabolism contributes to neurodegeneration via down-regulation of O-GlcNAcylation, which is regulated by glucose metabolism, and the resultant abnormal hyperphosphorylation of tau, which is crucial to neurodegeneration in AD.5

Peripheral glucose metabolism is mainly regulated by insulin. Recent studies have indicated that insulin signaling also regulates glucose metabolism in the brain and plays important roles in neural development and neuronal activities and affects learning and memory.6 The role of possible insulin dysfunction in AD has been suggested...
recently. However, how the impaired insulin signaling contributes to the pathogenesis of AD is not known.

To investigate the possible pathogenic mechanism related to the impaired brain insulin signaling and glucose metabolism in sporadic AD, we investigated insulin signaling pathways, glucose transporters (GLUT), protein O-GlcNAcylation and phosphorylation of tau and neurofilaments (NFs) in a rat model of sporadic AD, which was generated by intracerebroventricular (i.c.v.) injection of streptozotocin (STZ). STZ is a glucosamine-nitrosourea compound and is commonly administered peripherally to generate animal models of diabetes because of its ability to damage insulin-producing cells and to increase insulin resistance. We found the impaired insulin signaling pathway, overactivation of glycogen synthase kinase-3β (GSK-3β), decreased major glucose transporters, down-regulation of protein O-GlcNAcylation, increased phosphorylation of tau and NFs, and decreased microtubule-binding activity of tau in the brain of the rat model of AD. Our results provide in vivo evidence showing that impaired brain insulin signaling and O-GlcNAcylation contribute to hyperphosphorylation of tau and NFs.

Materials and Methods

Antibodies

Polyclonal antibodies against insulin receptor (IR), insulin-like growth factor-1 receptor β (IGF-1Rβ), the catalytic subunit phosphatidylinositol-3 kinase (PI3K), [PI3K(p110)] and the regulatory subunit [PI3K(p85)], as well as phosphorylated PI3K(p85), mitogen-activated protein kinase (MAPK), pMAPK, GSK-3β, and pGSK3β(S9) were bought from Cell Signaling, Inc. (Beverly, MA). Polyclonal antibodies against GLUT1 and GLUT3 were bought from Santa Cruz Biotechnology, Inc. (Santa Cruz, CA). A monoclonal antibody RL2 against O-GlycNAcylated proteins was bought from Affinity BioReagents (Golden, CO). A polyclonal antibody against O-GlcNAc transferase (OGT) and monoclonal antibody DM1A against tubulin were bought from Sigma-Aldrich Co. (St. Louis, MO). The phosphorylation-independent tau antibody R134d was raised in rabbits, as previously described. Polyclonal antibodies against site-specific tau phosphorylation were bought from BioSource International (Camarillo, CA). Monoclonal antibody PHF-1 was a gift from Dr. P. Davies of the Albert Einstein College of Medicine (Bronx, NY). The polyclonal antibody R61d against total NF was raised in our laboratory. The polyclonal antibody NF160 against NF-M was bought from Abcam, Inc. (Cambridge, MA). The monoclonal antibody SMI31 against phosphorylated NF-M/H was bought from Sternberger Monoclonals, Inc. (Baltimore, MD).

Animals and I.C.V. Injection

Wistar rats (male, 6 months old, weighing 280 to 320 g) from Charles River Laboratories (Wilmington, MA) were housed in a temperature-controlled room, and fed with standard rodent food pellets and water. They were housed for 1 week before use in our institutional animal colony. The use of animals was in accordance with the guidelines of the National Institutes of Health and was approved by the Animal Welfare Committee of the New York State Institute for Basic Research in Developmental Disabilities.

Rats were first anesthetized by an i.p. injection of 0.3% pentobarbital sodium (40 mg/kg). STZ (Sigma-Aldrich Co., St. Louis, MO) dissolved in 0.9% NaCl was injected into the bilateral ventricles of the brains at a dose of 1.5 mg/kg each site. The same volume (5 μl) of 0.9% NaCl alone was injected in control rats. The stereotaxic coordinates for the i.c.v. injection were: 0.9 mm posterior, 1.8 mm lateral, and 3.8 mm ventral from the Bregma. Three weeks (21 days) after i.c.v. injection, rats were euthanized with CO2, and the brains were removed immediately. The right hemisphere of each brain was frozen immediately and stored at −80°C for Western blots and microtubule binding experiments. The left hemispheres were fixed with 4% buffer-neutralized paraformaldehyde for immunohistochemical studies.

Western Blot Analysis

Brain tissue was homogenized in pre-chilled buffer containing 50 mmol/L Tris, pH 8.0, 150 mmol/L NaCl, 0.5 mmol/L EDTA, 1 mmol/L dithiothreitol, 1% NP-40, 0.5% sodium deoxycholate, 0.1% sodium dodecyl sulfate, 100 mmol/L sodium vanadate, 0.1 μmol/L 0-(2-acetamido-2-deoxy-d-glucopyranosylidone) amino-N-phenylcarbamate (PUGNAc), and a cocktail of protease inhibitors. Protein concentrations of the samples were measured by the modified Lowry method. The samples were resolved in 10% or 7.5% (for NF) SDS-polyacrylamide gel electrophoresis and electrotransferred onto Immobilon-P membrane (Millipore, Bedford, MA). The blots were then probed with primary antibodies and developed with the corresponding horseradish peroxidase-conjugated secondary antibody and enhanced chemiluminescence kit (Pierce, Rockford, IL). Densitometric quantification of protein bands in Western blots were analyzed using TINA software (Raytest IsotopenmeBgerate GmbH, Straubenhardt, Germany). Quantitative comparisons were analyzed by using student t-test, and the differences between groups were regarded to be significant when P < 0.05.

Immunofluorescence Staining

To detect the tau phosphorylation, paraffin sections (6-μm thickness) of the rat brains were developed with monoclonal antibody PHF-1, followed by anti-mouse IgG conjugated with Alexa488 (Molecular Probes, Eugene, OR). For NF staining, double-immunofluorescence staining was performed by using monoclonal antibody SM131 and polyclonal antibody NF160. The sections were then developed by using Alexa488-conjugated anti-mouse IgG and Alexa543-conjugated anti-rabbit IgG (Molecular Probes, Eugene, OR). In some experiments, the tissue sections were also counterstained with TO-PRO3, a nucleic acid-specific marker, to visualize the nuclei at a 633-nm excitation wavelength. Stained sections were examined by using a confocal microscope (PCM2000, Ni-
kon, Melville, NY). The negative control staining was performed simultaneously, in which the primary antibody was omitted.

**Microtubule Binding Assay**

Brain tissue was homogenized in a buffer (80 mmol/L PIPES, 0.5 mmol/L MgCl₂, 1 mmol/L EGTA) containing a protease inhibitor cocktail. The debris was removed by centrifugation at 16,000 × g at 4°C for 10 minutes. The resulting supernatants were heated and then centrifuged again at 10,000 × g at 4°C for 10 minutes to enrich heat-stable tau protein. The resulting supernatants were divided into several aliquots and mixed with taxol-stabilized microtubules prepared as described previously. After incubation at 32°C for 3 hours, the samples were centrifuged at 50,000 × g at 32°C for 30 minutes to separate the microtubules-bound tau from the unbound tau. The amounts of tau and tubulin (protein subunit of microtubules) in both fractions, as well as before centrifugation, were analyzed by quantitative Western blots developed with R134d and DM1A, respectively.

### Results

**Insulin Signaling Is Impaired in STZ-Treated Rat Brain**

To study the insulin signaling pathway in STZ-treated rat brain, we first determined the level of IR and IGF-1Rβ in brain homogenates. We did not find any difference in the levels of these two insulin receptors between the STZ-injected and control saline-injected rat brains (Figure 1A). However, the level of IR, but not of IGF-1Rβ, in the cerebrum was twofold that in the cerebellum. These results suggest that i.c.v. injection of STZ does not alter the expression of IR nor IGF-1Rβ in the brain.

To investigate whether STZ i.c.v. injection modulates the brain insulin signaling pathway via altering its activation, we determined the activation of the major downstream components of the insulin signaling pathway, including PI3K, GSK-3β, and MAPK, by measuring their site-specific phosphorylation, which is known to determine their activation. When IR is activated, it activates PI3K via phosphorylation of PI3K’s regulatory subunit, p85, at Tyr458. The activated PI3K then further activates its downstream kinase MAPK via phosphorylation at Thr202/Tyr204 (ERK1) or Thr183/Tyr185 (ERK2) and inactivates GSK-3β via phosphorylation at serine 9.

Quantitative Western blot analyses indicated that while STZ injection did not alter the levels of these kinases in the brain, it markedly decreased the phosphorylation levels of these kinases in the cerebrum, but not in the cerebellum (Figure 1B). These results suggest that STZ treatment resulted in impaired insulin signaling pathway in the rat cerebrum. There are two major MAPKs in the brain: ERK1 (p44) and ERK2 (p42). It is interesting that only the cerebral level of phosphorylated/activated ERK1 was markedly decreased in the STZ-treated rat brains, as compared with controls.

**Glucose Transporters Are Decreased in STZ-Treated Rat Brain**

We recently demonstrated that the major brain glucose transporters, GLUT1 and GLUT3, are decreased in AD brain, and this decrease is correlated to hyperphosphorylation of tau. Thus, we investigated whether i.c.v. administration of STZ affects these two GLUTs. We found that the levels of both GLUT1 and GLUT3 were markedly decreased in the STZ-treated rat brains.
decreased in the STZ-treated rat brains, as compared with the control-injected rat brains, but the decrease of GLUT1 did not reach a statistical significance in the cerebellum (Figure 2).

**STZ Causes a Decrease in Protein O-GlcNAcylation in Rat Brain**

Inefficient insulin signaling activity and glucose transporters can both lead to decreased intracellular glucose metabolism that could, in turn, lead to deficient intracellular UDP-GlcNAc and thus a decrease in protein O-GlcNAcylation. We therefore studied the protein O-GlcNAcylation level. We found that the protein O-GlcNAcylation level was decreased markedly in the cerebrum, but not cerebellum, of STZ-injected rats, as determined by Western blots developed with antibody RL2 (Figure 3A) or CTD110.6 (data not shown), both of which recognize O-GlcNAcylated proteins. We further determined the level of OGT, which catalyzes protein O-GlcNAcylation, and found that the OGT level in the cerebrum of STZ-injected rats was ~25% that found in control-injected rats (Figure 3B).

**STZ Induces Changes of Tau Phosphorylation and Decreases Its Microtubule-Binding Activity in Rat Brain**

Abnormal hyperphosphorylation and decreased activity of tau is one of the most important biochemical changes in AD-affected brain. Decreased brain glucose metabolism and O-GlcNAcylation can lead to hyperphosphorylation of tau in various systems. Hence, we studied phosphorylation of tau in STZ-treated rat brain. Western blots developed with a phosphorylation-independent tau antibody (R134d) indicated that the total tau level was not altered in STZ-treated rats. Tau phosphorylation was determined by Western blots developed with several phosphorylation-dependent and site-specific tau antibodies. Among nine different phosphorylation sites of tau we studied, STZ induced a significant increase in tau phosphorylation at Ser199, Thr212, and Ser396 in the cerebrum, but not at Ser202, Thr205, Ser214, Ser217, Ser262, or Ser422 (Figure 4, A and B). Consistent with the results observed with pS396 antibody, tau staining with the monoclonal antibody PHF-1, which recognizes tau phosphorylated at Ser396 and Ser404, also increased markedly in the STZ-treated rat brain (Figure 4, A and B). As expected, most antibodies detected three major tau bands that represent the major isoforms of tau in the rat brain. We also studied the immunohistochemical staining of the rat brain sections with PHF-1 antibody and observed an increased staining in the neuronal cell bodies and neurites in the cerebral cortex and the hippocampus of the STZ-treated rats (Figure 4C). The increased stain-
ing in neurites was more marked in the hippocampus. The nuclei of neurons were not stained by PHF-1.

Figure 4 also demonstrates the differences in tau level and tau phosphorylation between cerebrum and cerebellum. Cerebrum contained approximately 30% more tau protein than cerebellum, whereas the basic tau phosphorylation level in the cerebrum was much higher at several phosphorylation sites, including Ser199, Ser202, Thr205, Ser217, Ser396, and Ser422, than that in the cerebellum (Figure 4, A and B). The cerebellum was also found to be less affected by the STZ-induced alterations of tau phosphorylation.

To investigate if STZ treatment affected tau's biological activity, we enriched tau protein from rat brain extract and then incubated it with taxol-stabilized microtubules. The microtubule-bound tau was then separated from the unbound tau by sedimentation of microtubules by centrifugation. As expected, tubulin (protein subunit of microtubules) was found mostly in the pellet (P) fraction (Figure 5A). The amount of tau bound to microtubules (in the pellet) was dramatically less in samples from STZ-treated rat brains than from control-treated rat brains (Figure 5B). As a control experiment, all tau was found to be in the supernatant fraction when not incubated with microtubules (data not shown).

**STZ Increases Phosphorylation of NFs in Rat Brain**

Like tau, phosphorylation of NFs is also increased in AD-affected brain. Thus, we also determined phosphorylation level of NF-H and NF-M in STZ-treated rat brain by Western blots developed with monoclonal antibody SMI31, which recognizes only the phosphorylated form of NF-H and NF-M. We found that the STZ treatment led to increased phosphorylation of NF-H/M as compared with controls in the cerebrum, but not in the cerebellum (Figure 6, A and B). We also observed that the level of NF-M, but not of NF-H, was lower in rat cerebellum than cerebrum, as detected by both phosphorylation-independent antibodies R61d, which recognizes both NF-H and NF-M, and NF160, which is a NF-M-specific antibody (Figure 6A). However, the level of neither NF-H nor NF-M was affected by STZ treatment.

Immunohistochemical studies also demonstrated the increased NF phosphorylation in the tissue sections of STZ-treated rat cerebrum, as evidenced by triple immunofluorescence staining with antibodies SMI31 and NF160, as well as a nuclear marker TO-PRO3 (Figure 6C). Increased SMI31 staining was seen in the STZ-treated rat brains as compared with the control brains, whereas the phosphorylation-independent antibody NF160 did not show
any significant difference in immunoreactivity between the two groups.

**Discussion**

The insulin signaling pathway, including IR/IGF-1R and the downstream PI3K pathway, plays a critical role in the regulation of peripheral carbohydrate, lipid, and protein metabolism. Recent studies have indicated that insulin signaling also regulates glucose metabolism in the brain and plays important roles in neural development and neuronal activities and affect learning and memory.6 Although neurons also express insulin,26,27 the majority of the brain insulin is originated from the periphery through the blood brain barrier via a saturable transport mechanism.28 A role of possible insulin dysfunction in AD has been suggested recently.7,8 Binding of insulin to IR leads to its rapid autophosphorylation and activation of its tyrosine kinase activity, which recruits and phosphorylates different substrates, such as insulin receptor substrate-1. Tyrosine-phosphorylated insulin receptor substrate-substrate-1 then displays binding sites for various downstream signaling partners, of which PI3K is the major one. When PI3K is activated by phosphorylation at Tyr458 of the regulatory subunit p85, it leads to activation of the downstream pathways including the protein kinase B (AKT) and MAPK cascades.18 Recent studies suggest that insulin signaling is impaired in AD-affected brain.9,10 Some diabetic changes resulted from insulin resistance, such as the Maitland-reaction-related modifications and protein glycation, have also been observed in AD-affected brain.29–31 Because of the potentially significant role of impaired brain insulin signaling in AD, de la Monte and her colleagues9 recently proposed that AD is a type 3 diabetes. In this study, we found that in the brain of STZ rat model of AD, the activity of the insulin signaling is decreased, as evidenced by the decreased phosphorylation of PI3K and the downstream GSK-3β and MAPK. In a recent study, Grunblatt et al32 reported that the expression of IR is also decreased in rat brains 3 months after a single i.c.v. injection of a lower dose of STZ (1 mg/kg). Thus, the disturbance of insulin signaling may last for a long period of time in the STZ rat model of sporadic AD.

Because GSK-3β activity is negatively regulated by its phosphorylation at Ser9 with AKT, the impaired PI3K-AKT signaling leads to overactivation of GSK-3β due to the decreased phosphorylation at Ser9, which was indeed observed in the cerebrum of the STZ-injected rats. GSK-3β is known to be the most important kinase involved in regulation of tau phosphorylation and abnormal hyperphosphorylation of tau in AD-affected brain.33,34 Thus, brain insulin resistance can cause tau phosphorylation via activation of GSK-3β (Figure 7), which might be an early event in tau pathology. The positive immunostaining of early neurofibrillary tangles with anti-GSK-3β has been reported in AD-affected brain.35,36 In consistent with this notion, Ser199, Thr212, Ser396, and PHF-1 sites (Ser396 and Ser404) of tau, the phosphorylation of which was marked increased in the STZ-injected rat brains, are the GSK-3β sites.37,38

---

**Figure 6.** Alteration of phosphorylation of NF-H and NF-M in STZ-treated rat brains. A: Homogenates of cerebrum or cerebellum from rats after i.c.v. injection of STZ or control saline were analyzed by Western blots developed with either antibody SMI31 against the phosphorylated NF-H and NF-M or phosphorylation-independent antibodies R61d to NF-H/M or NF160 to NF-M. B: The respective NF bands in the blots, as shown in panel A, were quantified, and the relative SMI31 immunoreactivities (mean ± SE), after normalization with the respective R61d immunoreactive bands, are shown. *P < 0.05 vs. controls. C: Triple immunofluorescence staining of rat brain tissue sections with SMI31, NF160, and a nuclear marker TO-PRO3. Scale bar = 12.5 μm.
MAPK (ERK1 and ERK2) can be activated by PI3K via Rac and PAK, which is consistent with our observations of down-regulation of both PI3K and MAPK in the STZ-injected rat brains. However, MAPK can also be activated by many other factors and under various conditions. Besides the impairment of insulin signaling and glucose metabolism, inflammation has been well documented in AD-affected brain, which could stimulate activation of MAPK.39 Activated MAPK (pERK1/2) has been reported to associate with neurofibrillary tangles in AD.40,41 The net activation of MAPK in AD-affected brain is probably because the activation had overridden the down-regulation induced by the impairment of insulin signaling and glucose metabolism. In the present study, we observed that the activation level of only ERK1, but not of ERK2, was decreased significantly in the STZ-injected rat cerebrum, suggesting that ERK1 activation is regulated by the insulin-PI3K pathway. Whether ERK1 and ERK2 play any different roles in AD pathogenesis is currently not known.

Glucose is the primary source of the energy required for brain activity, although it cannot enter the brain freely. The transport of glucose from the bloodstream into the brain is mediated by GLUTs. To date, 14 GLUTs have been reported in the human tissue.42 In mammalian brain, GLUT1 and GLUT3 are the predominant GLUTs responsible for glucose transport.63 Decreased GLUT1 and GLUT3 have been observed in AD-affected brain,44–46 and this decrease associates with decreased O-GlcNAcylation and abnormal hyperphosphorylation of tau in AD-affected brain,19 suggesting that the decrease may contribute to tau pathology and neurodegeneration in AD. In the present study, we found that the GLUT1 and GLUT3 levels were also decreased in the icv STZ-injected rat brains. This decrease might be resulted from...
the STZ-induced impaired insulin signaling, because the GLUT expression is mainly regulated by hypoxia-inducible factor-1α that, in turn, regulated by the PI3K pathway via AKT, mammalian target of rapamycin, and p70S6K (Figure 7). The observations of the decrease in GLUT1 and GLUT3 in the STZ-treated rat brains further support the relevance of this rat model for sporadic AD.

Protein O-GlcNAcylation is a common dynamic post-translational modification of nucleocytoplasmic proteins. This modification is mainly regulated by intracellular glucose metabolism via hexosamine biosynthetic pathway and thus is also regarded as a sensor of glucose metabolism. A reciprocal relationship between O-GlcNAcylation and phosphorylation has been observed in many proteins including tau and NF. Our recent studies suggest that in AD-affected brain, the impaired glucose metabolism may have led to down-regulation of O-GlcNAcylation that, in turn, facilitates abnormal hyperphosphorylation of tau and neurodegeneration. These alterations seen in AD-affected brain were also observed in the present study in the STZ rat model of sporadic AD, further suggesting the role of down-regulation of O-GlcNAcylation in AD pathogenesis. Consistent with our conclusions, a recent study has demonstrated that elevation of brain O-GlcNAcylation by a pharmacological method inhibit tau phosphorylation in vivo. In the STZ rat brain, the down-regulation of O-GlcNAcylation may be caused not only by STZ-induced decrease in glucose metabolism and GLUT1/3, but also by down-regulation of OGT, the enzyme that catalyzes protein O-GlcNAcylation. It is interesting to note that the significant decrease in O-GlcNAcylation and OGT was seen only in the cerebrum, but not in the cerebellum, of the STZ rat model. This phenomenon coincides with the fact that only the cerebrum is affected in AD, and cerebellum is almost intact in AD.

Tau and NF are hyperphosphorylated and accumulated in AD-affected brain. The abnormal hyperphosphorylation of tau is the most characteristic biochemical change in AD brain and is critical to the formation of neurofibrillary tangles, the hallmark brain lesion of AD. Therefore, we investigated tau phosphorylation at ten individual phosphorylation sites, which are hyperphosphorylated in AD-affected brain, in the STZ rat model in this study. Among these phosphorylation sites, we found a marked increase in tau phosphorylation at Ser199, Thr212, Ser396, and PHF-1 sites (Ser396 and Ser404) in the STZ-injected rat brains. This finding is consistent with the involvement of the cerebrum, among the central nervous system, in AD.

Neurofibrillary degeneration is a chronic neurodegenerative process characterized by filamentous aggregation of tau in the affected neurons. Despite of many studies focused on tau abnormalities and neurofibrillary degeneration, the exact sequential changes in tau and neurofibrillary formation during the development of AD remain to be elucidated. It has been proposed that abnormal hyperphosphorylation of tau is an initial critical alteration that induces the subsequent conformational changes, a loss of its biological activity, and a gain of a toxic activity, and leads to its polymerization into neurofibrillary tangles. Our findings of increased phosphorylation and decreased microtubule-binding activity of tau in the STZ-injected rat brains support the above notion. Tau isolated from AD is found to be phosphorylated at as many as 40 sites. Not all these phosphorylation sites are equally important to the pathological changes of tau or are hyperphosphorylated at the same time. Among the ten phosphorylation sites studied, we found a marked increase in tau phosphorylation at Ser199, Thr212, Ser396, and PHF-1 sites (Ser396 and Ser404) in the STZ-injected rat brains. These sites of tau are also hyperphosphorylated in PC12 cells cultured under the glucose deficient condition and in the brains of fasting mice. Thus, it is likely that the increased tau phosphorylation we observed in the rat AD model results from STZ-induced decrease in brain glucose metabolism in addition to GSK-3β activation. Furthermore, we found that the microtubule-binding activity of tau enriched from the STZ-treated rats was reduced. These observations suggest that, in addition to previously recognized phosphorylation sites at the microtubule-binding domains, tau phosphorylation at Ser199, Thr212, and/or Ser396/404 may also affect tau’s biological activity to bind to microtubules. These findings are consistent with our recent studies showing decreased biological activity of tau after phosphorylation by DyRK1A (dual-specificity tyrosine-phosphorylated and regulated kinase 1A) that phosphorylates tau mainly at Thr212. Thr212 and Ser396/404 are also among those phosphorylation sites whose phosphorylation levels differ dramatically between tau in the fetal brain and the pathological tau in AD-affected brain. It is worth noting that Ser199, Ser202, Thr205, Thr212, Ser396, and Ser404 of tau can also be phosphorylated by ERK in vitro. Despite the decrease in ERK1 activation, tau phosphorylation levels at these sites were increased, rather than decreased, in the STZ-injected rat brains, suggesting that ERK1 might not play a significant role in phosphorylating tau directly in the brain. Except for Thr212, increased phosphorylation of tau was only seen in the cerebrum, but not cerebellum of the STZ-treated rats. This finding is consistent with the involvement of the cerebrum, among the central nervous system, in AD.
ery. Our observations of decreased insulin signaling activity in the cerebrum of STZ-treated rat brain are consistent with this hypothesis. Decreased glucose utilization, cholinergic deficiency, increased oxidative stress and glial activation in the brain, as well as impairments in learning and memory have been reported previously in the STZ rat model of sporadic AD [for review, see 65]. In the present study, we further demonstrated the impaired insulin signaling pathway, increased GSK-3β activation, decreased major glucose transporters, down-regulation of protein O-GlcNAcylation, increased phosphorylation of tau and NF, and decreased microtubule-binding activity of tau in the brain. All these abnormalities observed in the STZ rat model of AD have been documented in patients with sporadic AD. Taken together, we propose that brain insulin resistance, which occurs in AD-affected brain and in the STZ-injected rat brain, could lead to neurofibrillary degeneration via two additive, or synergistic, pathways (Figure 7). First, brain insulin resistance leads to decreased PI3K-AKT signaling activity, resulting in overactivation of GSK-3β. Overactivation of GSK-3β not only leads to hyperphosphorylation of tau directly, but also causes cognitive impairments via other pathways.56,67 Second, insulin resistance also leads to decreased GLUT1/3 expression and glucose uptake/metabolism in the brain. Decreased intraneuronal glucose metabolism results in decreased level of UDP-GlcNAc and, consequently, decreased tau O-GlcNAcylation. Because the latter regulates tau phosphorylation inversely,3–5 decreased O-GlcNAcylation could lead to hyperphosphorylation of tau, which, in turn, turns tau protein into toxic oligomers and eventually leads to neurodegeneration in AD and the learning and memory deficits in the STZ-injected rats.

References

19. McKay MM, Morrison DK: Integrating signals from RTKs to ERK/ MAPK. Oncogene 2007, 26:3113–3121


